Durvalumab联合Tremelimumab治疗后不久肝细胞癌并发暴发性1型糖尿病1例

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2024-12-26 DOI:10.2169/internalmedicine.4688-24

Nanase Usui, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Nobuaki Nakayama, Tomoaki Tomiya, Suguru Mizuno, Satoshi Mochida

{"title":"Durvalumab联合Tremelimumab治疗后不久肝细胞癌并发暴发性1型糖尿病1例","authors":"Nanase Usui, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Nobuaki Nakayama, Tomoaki Tomiya, Suguru Mizuno, Satoshi Mochida","doi":"10.2169/internalmedicine.4688-24","DOIUrl":null,"url":null,"abstract":"A 64-year-old man with cirrhosis was diagnosed with unresectable hepatocellular carcinoma and treated with a combination of durvalumab and tremelimumab. The patient had no history of diabetes mellitus. Three weeks later, the patient developed general fatigue, dry mouth, and polyuria. A subsequent blood examination revealed a blood glucose level of 706 mg/dL and C-peptide level of 0.29 ng/mL, with an HbA1c of 6.4%. The patient was diagnosed with fulminant type 1 diabetes mellitus. Although fulminant type 1 diabetes mellitus is a rare immune-mediated adverse event, it requires prompt attention shortly after the initiation of these agents owing to its severe and emergent nature.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Case of Hepatocellular Carcinoma Complicated by Fulminant Type 1 Diabetes Mellitus Shortly After Initiation of Durvalumab Plus Tremelimumab.\",\"authors\":\"Nanase Usui, Yukinori Imai, Kayoko Sugawara, Yoshihito Uchida, Nobuaki Nakayama, Tomoaki Tomiya, Suguru Mizuno, Satoshi Mochida\",\"doi\":\"10.2169/internalmedicine.4688-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 64-year-old man with cirrhosis was diagnosed with unresectable hepatocellular carcinoma and treated with a combination of durvalumab and tremelimumab. The patient had no history of diabetes mellitus. Three weeks later, the patient developed general fatigue, dry mouth, and polyuria. A subsequent blood examination revealed a blood glucose level of 706 mg/dL and C-peptide level of 0.29 ng/mL, with an HbA1c of 6.4%. The patient was diagnosed with fulminant type 1 diabetes mellitus. Although fulminant type 1 diabetes mellitus is a rare immune-mediated adverse event, it requires prompt attention shortly after the initiation of these agents owing to its severe and emergent nature.\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.4688-24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4688-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

一名64岁肝硬化男性被诊断为不可切除的肝细胞癌，并接受durvalumab和tremelimumab联合治疗。患者无糖尿病病史。三周后，患者出现全身乏力、口干和多尿。随后的血液检查显示血糖水平为706 mg/dL， c肽水平为0.29 ng/mL， HbA1c为6.4%。患者被诊断为暴发性1型糖尿病。虽然暴发性1型糖尿病是一种罕见的免疫介导的不良事件，但由于其严重和紧急的性质，在这些药物开始使用后不久就需要立即引起注意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Case of Hepatocellular Carcinoma Complicated by Fulminant Type 1 Diabetes Mellitus Shortly After Initiation of Durvalumab Plus Tremelimumab.

A 64-year-old man with cirrhosis was diagnosed with unresectable hepatocellular carcinoma and treated with a combination of durvalumab and tremelimumab. The patient had no history of diabetes mellitus. Three weeks later, the patient developed general fatigue, dry mouth, and polyuria. A subsequent blood examination revealed a blood glucose level of 706 mg/dL and C-peptide level of 0.29 ng/mL, with an HbA1c of 6.4%. The patient was diagnosed with fulminant type 1 diabetes mellitus. Although fulminant type 1 diabetes mellitus is a rare immune-mediated adverse event, it requires prompt attention shortly after the initiation of these agents owing to its severe and emergent nature.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.